Identification of molecular markers specific for pancreatic neuroendocrine tumors by genetic profiling of core biopsies

Mark Bloomston, Alan Durkin, Ivana Yang, Mumtaz V Rojiani, Alexander S. Rosemurgy, Steven Enkmann, Timothy J. Yeatman, Emmanuel E. Zervos

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: There is a paucity of known molecular markers that distinguish pancreatic neuroendocrine tumors from other pancreatic tumor types. We hypothesized that novel markers for pancreatic neuroendocrine tumors could be identified with molecular fingerprinting of pooled RNA samples from core biopsies. Methods: Total RNA was harvested from nine core biopsies of normal pancreas, pancreatitis, pancreatic adenocarcinoma, pancreatic adenocarcinoma metastases, and pancreatic neuroendocrine tumors. RNA from each group of samples was pooled and hybridized to an oligonucleotide-based microarray. Four genes (ANG2, NPDC1, ELOVL4, and CALCR) were selected for further investigation by reverse transcriptase polymerase chain reaction from the top 20 highest expressed genes, on the basis of potential as novel markers. Results: Neuroendocrine tumors were most unique from normal pancreas. Pancreatitis, pancreatic adenocarcinoma, and metastases are more closely related to each other and to normal pancreas. ANG2 was overexpressed in 89% of neuroendocrine tumors, compared with 22% of normal pancreas, making it the best potential molecular marker or therapeutic target of the four genes selected for analysis. Conclusion: We have identified a specific set of molecular markers for pancreatic neuroendocrine tumors distinct from pancreatitis and pancreatic adenocarcinoma. These novel markers may prove useful as molecular markers or therapeutic targets unique to pancreatic neuroendocrine tumors.

Original languageEnglish (US)
Pages (from-to)413-419
Number of pages7
JournalAnnals of surgical oncology
Volume11
Issue number4
DOIs
StatePublished - Dec 1 2004

Fingerprint

Neuroendocrine Tumors
Biopsy
Pancreas
Adenocarcinoma
Pancreatitis
RNA
Neoplasm Metastasis
Genes
Oligonucleotide Array Sequence Analysis
Reverse Transcriptase Polymerase Chain Reaction
Therapeutics
Neoplasms

Keywords

  • Genetics
  • Microarray
  • Neuroendocrine
  • Pancreas

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Identification of molecular markers specific for pancreatic neuroendocrine tumors by genetic profiling of core biopsies. / Bloomston, Mark; Durkin, Alan; Yang, Ivana; Rojiani, Mumtaz V; Rosemurgy, Alexander S.; Enkmann, Steven; Yeatman, Timothy J.; Zervos, Emmanuel E.

In: Annals of surgical oncology, Vol. 11, No. 4, 01.12.2004, p. 413-419.

Research output: Contribution to journalArticle

Bloomston, Mark ; Durkin, Alan ; Yang, Ivana ; Rojiani, Mumtaz V ; Rosemurgy, Alexander S. ; Enkmann, Steven ; Yeatman, Timothy J. ; Zervos, Emmanuel E. / Identification of molecular markers specific for pancreatic neuroendocrine tumors by genetic profiling of core biopsies. In: Annals of surgical oncology. 2004 ; Vol. 11, No. 4. pp. 413-419.
@article{13424596e9dd4f5ea8330a27fda9ab51,
title = "Identification of molecular markers specific for pancreatic neuroendocrine tumors by genetic profiling of core biopsies",
abstract = "Background: There is a paucity of known molecular markers that distinguish pancreatic neuroendocrine tumors from other pancreatic tumor types. We hypothesized that novel markers for pancreatic neuroendocrine tumors could be identified with molecular fingerprinting of pooled RNA samples from core biopsies. Methods: Total RNA was harvested from nine core biopsies of normal pancreas, pancreatitis, pancreatic adenocarcinoma, pancreatic adenocarcinoma metastases, and pancreatic neuroendocrine tumors. RNA from each group of samples was pooled and hybridized to an oligonucleotide-based microarray. Four genes (ANG2, NPDC1, ELOVL4, and CALCR) were selected for further investigation by reverse transcriptase polymerase chain reaction from the top 20 highest expressed genes, on the basis of potential as novel markers. Results: Neuroendocrine tumors were most unique from normal pancreas. Pancreatitis, pancreatic adenocarcinoma, and metastases are more closely related to each other and to normal pancreas. ANG2 was overexpressed in 89{\%} of neuroendocrine tumors, compared with 22{\%} of normal pancreas, making it the best potential molecular marker or therapeutic target of the four genes selected for analysis. Conclusion: We have identified a specific set of molecular markers for pancreatic neuroendocrine tumors distinct from pancreatitis and pancreatic adenocarcinoma. These novel markers may prove useful as molecular markers or therapeutic targets unique to pancreatic neuroendocrine tumors.",
keywords = "Genetics, Microarray, Neuroendocrine, Pancreas",
author = "Mark Bloomston and Alan Durkin and Ivana Yang and Rojiani, {Mumtaz V} and Rosemurgy, {Alexander S.} and Steven Enkmann and Yeatman, {Timothy J.} and Zervos, {Emmanuel E.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1245/ASO.2004.03.077",
language = "English (US)",
volume = "11",
pages = "413--419",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Identification of molecular markers specific for pancreatic neuroendocrine tumors by genetic profiling of core biopsies

AU - Bloomston, Mark

AU - Durkin, Alan

AU - Yang, Ivana

AU - Rojiani, Mumtaz V

AU - Rosemurgy, Alexander S.

AU - Enkmann, Steven

AU - Yeatman, Timothy J.

AU - Zervos, Emmanuel E.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Background: There is a paucity of known molecular markers that distinguish pancreatic neuroendocrine tumors from other pancreatic tumor types. We hypothesized that novel markers for pancreatic neuroendocrine tumors could be identified with molecular fingerprinting of pooled RNA samples from core biopsies. Methods: Total RNA was harvested from nine core biopsies of normal pancreas, pancreatitis, pancreatic adenocarcinoma, pancreatic adenocarcinoma metastases, and pancreatic neuroendocrine tumors. RNA from each group of samples was pooled and hybridized to an oligonucleotide-based microarray. Four genes (ANG2, NPDC1, ELOVL4, and CALCR) were selected for further investigation by reverse transcriptase polymerase chain reaction from the top 20 highest expressed genes, on the basis of potential as novel markers. Results: Neuroendocrine tumors were most unique from normal pancreas. Pancreatitis, pancreatic adenocarcinoma, and metastases are more closely related to each other and to normal pancreas. ANG2 was overexpressed in 89% of neuroendocrine tumors, compared with 22% of normal pancreas, making it the best potential molecular marker or therapeutic target of the four genes selected for analysis. Conclusion: We have identified a specific set of molecular markers for pancreatic neuroendocrine tumors distinct from pancreatitis and pancreatic adenocarcinoma. These novel markers may prove useful as molecular markers or therapeutic targets unique to pancreatic neuroendocrine tumors.

AB - Background: There is a paucity of known molecular markers that distinguish pancreatic neuroendocrine tumors from other pancreatic tumor types. We hypothesized that novel markers for pancreatic neuroendocrine tumors could be identified with molecular fingerprinting of pooled RNA samples from core biopsies. Methods: Total RNA was harvested from nine core biopsies of normal pancreas, pancreatitis, pancreatic adenocarcinoma, pancreatic adenocarcinoma metastases, and pancreatic neuroendocrine tumors. RNA from each group of samples was pooled and hybridized to an oligonucleotide-based microarray. Four genes (ANG2, NPDC1, ELOVL4, and CALCR) were selected for further investigation by reverse transcriptase polymerase chain reaction from the top 20 highest expressed genes, on the basis of potential as novel markers. Results: Neuroendocrine tumors were most unique from normal pancreas. Pancreatitis, pancreatic adenocarcinoma, and metastases are more closely related to each other and to normal pancreas. ANG2 was overexpressed in 89% of neuroendocrine tumors, compared with 22% of normal pancreas, making it the best potential molecular marker or therapeutic target of the four genes selected for analysis. Conclusion: We have identified a specific set of molecular markers for pancreatic neuroendocrine tumors distinct from pancreatitis and pancreatic adenocarcinoma. These novel markers may prove useful as molecular markers or therapeutic targets unique to pancreatic neuroendocrine tumors.

KW - Genetics

KW - Microarray

KW - Neuroendocrine

KW - Pancreas

UR - http://www.scopus.com/inward/record.url?scp=3142769031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142769031&partnerID=8YFLogxK

U2 - 10.1245/ASO.2004.03.077

DO - 10.1245/ASO.2004.03.077

M3 - Article

C2 - 15070602

AN - SCOPUS:3142769031

VL - 11

SP - 413

EP - 419

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 4

ER -